Future growth expectations in sales/revenue/volumes?

Concord Biotech aims for a CAGR growth of around 25% over the next five to six years, up from a historical 18% CAGR. Growth will be driven by multiple levers including API and finished formulation businesses. Recently gained US FDA approval and inclusion of the Limbasi facility in customer dossiers are expected to boost growth. Injectable business is anticipated to start contributing in subsequent years. New R&D products, with 1-2 expected to be commercialized annually, will add to growth. Growth depends on how generic players enter markets post-patent expiry, with opportunities in extended-re

Future growth expectations in earnings/operating earnings/profits/EPS?

Concord Biotech expects to grow at a CAGR of around 25% over the next five to six years, up from a historical CAGR of 18%. Growth drivers include expansion in both API and finished formulations, US FDA approvals, increased inclusion of Limbasi facility in customer dossiers, and a ramp-up in the injectable business. New R&D products (1-2 commercialized annually) will contribute progressively to growth. Operational efficiencies have supported EBITDA margin expansion, expected to improve further with sales growth. Capacity utilization is anticipated to reach 70-78% over a 4-5 year timefra

Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the provided transcript of Concord Biotech Limited's Q2 and H1 FY24 earnings call. The management focuses on growth strategies, capacity utilization, regulatory approvals, and revenue guidance without discussing raising capital. Discussions highlight organic growth opportunities, new customer additions, and product commercialization rather than external financing. No references were made to debt financing, equity issuance, or capital raising plans during the Q&A or management commentary sections.

Any current/future capex/capital investment/strategic investment?

Concord Biotech plans to commercialize its injectable manufacturing facility at Valthera by December 2023 (Q4 FY24). The injectable plant is targeted primarily towards India and emerging markets, with potential regulatory filings and inspections expected in the next financial year. The company has expanded capacity significantly, especially at the Limbasi facility, and anticipates reaching 70-78% utilization over a 4-5 year period, indicating ongoing investment in capacity expansion. Long-term strategy includes medium to long-term CDMO (Contract Development and Manufacturing Organization) oppo

Concord BiotechQ2 FY24Pharmaceuticals & Biotechnology

Concord Biotech Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,374P/E: 53.5Market Cap: ₹15.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Concord Biotech aims for a CAGR growth of around 25% over the next five to six years, up from a historical 18% CAGR.
Growth will be driven by multiple levers including API and finished formulation businesses.
Recently gained US FDA approval and inclusion of the Limbasi facility in customer dossiers are expected to boost growth.
Injectable business is anticipated to start contributing in subsequent years.
New R&D products, with 1-2 expected to be commercialized annually, will add to growth.
Growth depends on how generic players enter markets post-patent expiry, with opportunities in extended-release and gel formulations.
Expansion into oncology and anti-infective segments, along with wallet share gains from existing customers and addition of new customers, will support revenue increases.
Capacity utilization is expected to rise gradually, reaching 70-78% over a 4-5 year timeframe.

Margin guidance

Category 1

Concord Biotech expects to grow at a CAGR of around 25% over the next five to six years, up from a historical CAGR of 18%.
Growth drivers include expansion in both API and finished formulations, US FDA approvals, increased inclusion of Limbasi facility in customer dossiers, and a ramp-up in the injectable business.
New R&D products (1-2 commercialized annually) will contribute progressively to growth.
Operational efficiencies have supported EBITDA margin expansion, expected to improve further with sales growth.
Capacity utilization is anticipated to reach 70-78% over a 4-5 year timeframe, supporting sustained margin and profit growth.
The company is confident of outperforming industry growth with stable pricing and volume-driven revenue expansion.
FY24 guidance remains conservative at 18%+ growth despite a strong H1 performance (35% growth), aiming for consistent and sustainable profitability improvements.

See what Concord Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity in the provided transcript of Concord Biotech Limited's Q2 and H1 FY24 earnings call.
The management focuses on growth strategies, capacity utilization, regulatory approvals, and revenue guidance without discussing raising capital.
Discussions highlight organic growth opportunities, new customer additions, and product commercialization rather than external financing.
No references were made to debt financing, equity issuance, or capital raising plans during the Q&A or management commentary sections.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Concord Biotech Limited. However, relevant inferred points related to demand and customer engagement are: - Customers' annual demand is stable, without changes forecasted, indicating a steady order flow (Page 13). - There is some quarter-to-quarter lumpiness in orders due to customers' production schedules causing pre-ponement or postponement (Page 13). - About 25 new customers have been added in the last six months across API and formulation segments, suggesting order book expansion (Page 20). - Growth is driven both by increased wallet share from existing customers and addition of new customers (Page 27). - Engagement with potential new large customers for CDMO opportunities is ongoing but expected medium to long term (Page 25). - Recent USFDA approval and inclusion of Limbasi facility in customer dossiers are expected to drive gradual growth and new orders (Page 31). No specific numeric order book values or pending orders were disclosed.

See what Concord Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes

Concord Biotech plans to commercialize its injectable manufacturing facility at Valthera by December 2023 (Q4 FY24).
The injectable plant is targeted primarily towards India and emerging markets, with potential regulatory filings and inspections expected in the next financial year.
The company has expanded capacity significantly, especially at the Limbasi facility, and anticipates reaching 70-78% utilization over a 4-5 year period, indicating ongoing investment in capacity expansion.
Long-term strategy includes medium to long-term CDMO (Contract Development and Manufacturing Organization) opportunities, with ongoing engagements to build capabilities and customer relationships.
The shift from 18% CAGR growth historically to 25% CAGR over the next 5-6 years implies continued capital investment to support this growth.
No specific dollar values or new capital projects beyond the injectable facility and capacity expansions are detailed in the transcript.

Track Concord Biotech — get its next earnings analysis in your feed

How does Concord Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisConcord Biotech

Rev 2Mar 1

See where Concord Biotech sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Concord Biotech rank in Pharmaceuticals & Biotechnology?

Compare Concord Biotech against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Concord Biotech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →